To determine whether ACH has meaningful or significant anti-obesity or anti-diabetic effects, further research, including pharmacokinetic and pharmacological studies, in vivo experiments under physiological conditions, and potentially human clinical trials, is necessary. This evidence concerns the gene FGFR3 and obesity disorder.